The Globe and Mail reports in its Saturday edition that Raymond James analyst Michael Freeman rates Well Health Technologies "outperform" in new coverage. The Globe's David Leeder writes that Mr. Freeman set a share target of $8.50. Analysts on average target the shares at $7.96. Mr. Freeman says Well Health has "become the centre of gravity in Canada's primary healthcare and digital health ecosystem, and is a rapidly ascendant power in U.S. hybrid care, growing by way of disciplined, accretive M&A." He says in a note: "Well Health leverages its large, growing footprint of physical clinics, combined with its increasingly broad and interconnected suite of digital tools to empower healthcare practitioners and patients, looking to improve health outcomes and yield efficiencies in overstressed healthcare markets often fraught with long wait-times and outdated tech. Well Health's two broad operating categories -- omni-channel patient services and virtual service -- are core to the company's hybrid approach to healthcare, enabling [it] to leverage cross-platform operational and technological synergies, and situating the company nicely to take advantage of structural and capital markets-oriented tailwinds."